{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:35:43Z","timestamp":1790847343797,"version":"4.1.0"},"reference-count":135,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":1152,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T00:00:00Z","timestamp":1650153600000},"content-version":"vor","delay-in-days":502,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013748","name":"Hope Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013748","name":"Hope Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Osteogenesis imperfecta (OI) describes a series of genetic bone fragility disorders that can have a substantive impact on patient quality of life. The multidisciplinary approach to management of children and adults with OI primarily involves the administration of antiresorptive medication, allied health (physiotherapy and occupational therapy), and orthopedic surgery. However, advances in gene editing technology and gene therapy vectors bring with them the promise of gene-targeted interventions to provide an enduring or perhaps permanent cure for OI. This review describes emergent technologies for cell- and gene-targeted therapies, major hurdles to their implementation, and the prospects of their future success with a focus on bone disorders. \u00a9 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).<\/jats:p>","DOI":"10.1002\/jbmr.4549","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T08:23:58Z","timestamp":1647764638000},"page":"826-836","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Curative Cell and Gene Therapy for Osteogenesis Imperfecta"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-6281","authenticated-orcid":false,"given":"Aaron","family":"Schindeler","sequence":"first","affiliation":[{"name":"Children's Hospital Westmead Clinical School University of Sydney Camperdown Australia"},{"name":"Bioengineering and Molecular Medicine Laboratory the Children's Hospital at Westmead and the Westmead Institute for Medical Research Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9094-7171","authenticated-orcid":false,"given":"Lucinda R","family":"Lee","sequence":"additional","affiliation":[{"name":"Children's Hospital Westmead Clinical School University of Sydney Camperdown Australia"},{"name":"Bioengineering and Molecular Medicine Laboratory the Children's Hospital at Westmead and the Westmead Institute for Medical Research Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2267-3671","authenticated-orcid":false,"given":"Alexandra K","family":"O'Donohue","sequence":"additional","affiliation":[{"name":"Children's Hospital Westmead Clinical School University of Sydney Camperdown Australia"},{"name":"Bioengineering and Molecular Medicine Laboratory the Children's Hospital at Westmead and the Westmead Institute for Medical Research Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0876-6292","authenticated-orcid":false,"given":"Samantha L","family":"Ginn","sequence":"additional","affiliation":[{"name":"Gene Therapy Research Unit, Children's Medical Research Institute, Faculty of Medicine and Health The University of Sydney and Sydney Children's Hospitals Network Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5898-5808","authenticated-orcid":false,"given":"Craig F","family":"Munns","sequence":"additional","affiliation":[{"name":"Child Health Research Centre and Faculty of Medicine The University of Queensland Brisbane Queensland Australia"},{"name":"Department of Endocrinology and Diabetes Queensland Children's Hospital Brisbane QLD Australia"},{"name":"Faculty of Medicine The University of Queensland Brisbane QLD Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,20]]},"reference":[{"key":"2024012713595445700_jbmr4549-bib-0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2019.04.021","article-title":"Mendelian bone fragility disorders","volume":"126","author":"Robinson","year":"2019","journal-title":"Bone."},{"issue":"3","key":"2024012713595445700_jbmr4549-bib-0002","doi-asserted-by":"crossref","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","volume":"18","author":"Marini","year":"2017","journal-title":"Osteogenesis imperfecta. Nat Rev Dis Primers."},{"issue":"2","key":"2024012713595445700_jbmr4549-bib-0003","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet."},{"issue":"12","key":"2024012713595445700_jbmr4549-bib-0004","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1007\/s00198-016-3709-1","article-title":"DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum","volume":"27","author":"Bardai","year":"2016","journal-title":"Osteoporos Int."},{"issue":"8","key":"2024012713595445700_jbmr4549-bib-0005","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1359\/jbmr.070418","article-title":"Natural history of hyperplastic callus formation in osteogenesis imperfecta type V","volume":"22","author":"Cheung","year":"2007","journal-title":"J Bone Miner Res."},{"key":"2024012713595445700_jbmr4549-bib-0006","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/JMDH.S113483","article-title":"Managing the patient with osteogenesis imperfecta: a multidisciplinary approach","volume":"10","author":"Marr","year":"2017","journal-title":"J Multidiscip Healthc."},{"issue":"5","key":"2024012713595445700_jbmr4549-bib-0007","doi-asserted-by":"crossref","first-page":"e10118","DOI":"10.1002\/jbm4.10118","article-title":"A multicenter observational cohort study to evaluate the effects of bisphosphonate exposure on bone mineral density and other health outcomes in osteogenesis imperfecta","volume":"3","author":"Bains","year":"2019","journal-title":"JBMR Plus"},{"issue":"2","key":"2024012713595445700_jbmr4549-bib-0008","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4158\/EP171910.OR","article-title":"Zoledronic acid versus alendronate in the treatment of children with osteogenesis imperfecta: a 2-year clinical study","volume":"24","author":"Lv","year":"2018","journal-title":"Endocr Pract."},{"key":"2024012713595445700_jbmr4549-bib-0009","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bone.2019.06.011","article-title":"Effects of zoledronic acid on vertebral shape of children and adolescents with osteogenesis imperfecta","volume":"127","author":"Li","year":"2019","journal-title":"Bone."},{"issue":"3","key":"2024012713595445700_jbmr4549-bib-0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ajhg.2010.01.034","article-title":"Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta","volume":"86","author":"Christiansen","year":"2010","journal-title":"Am J Hum Genet"},{"issue":"3","key":"2024012713595445700_jbmr4549-bib-0011","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/jbmr.250","article-title":"Mutations in FKBP10 cause recessive osteogenesis imperfecta and Bruck syndrome","volume":"26","author":"Kelley","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024012713595445700_jbmr4549-bib-0012","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3389\/fgene.2020.00984","article-title":"Genotypic and phenotypic analysis in Chinese cohort with autosomal recessive osteogenesis imperfecta","volume":"11","author":"Li","year":"2020","journal-title":"Front Genet."},{"issue":"5","key":"2024012713595445700_jbmr4549-bib-0013","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/ajmg.a.36427","article-title":"Report of a newly indentified patient with mutations in BMP1 and underlying pathogenetic aspects","volume":"164A","author":"Valencia","year":"2014","journal-title":"Am J Med Genet A."},{"issue":"4","key":"2024012713595445700_jbmr4549-bib-0014","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ajhg.2009.09.001","article-title":"PPIB mutations cause severe osteogenesis imperfecta","volume":"85","author":"van Dijk","year":"2009","journal-title":"Am J Hum Genet"},{"issue":"2","key":"2024012713595445700_jbmr4549-bib-0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2006.08.039","article-title":"CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta","volume":"127","author":"Morello","year":"2006","journal-title":"Cell."},{"issue":"1","key":"2024012713595445700_jbmr4549-bib-0016","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00223-016-0201-z","article-title":"Novel mutations in SERPINF1 result in rare osteogenesis imperfecta type VI","volume":"100","author":"Wang","year":"2017","journal-title":"Calcif Tissue Int."},{"issue":"2","key":"2024012713595445700_jbmr4549-bib-0017","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ajhg.2012.06.005","article-title":"A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V","volume":"91","author":"Cho","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"12","key":"2024012713595445700_jbmr4549-bib-0018","doi-asserted-by":"crossref","first-page":"e1525","DOI":"10.1002\/mgg3.1525","article-title":"A novel mutation in PLS3 causes extremely rare X-linked osteogenesis imperfecta","volume":"8","author":"Hu","year":"2020","journal-title":"Mol Genet Genomic Med"},{"issue":"4","key":"2024012713595445700_jbmr4549-bib-0019","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00198-016-3866-2","article-title":"Novel mutations in the SEC24D gene in Chinese families with autosomal recessive osteogenesis imperfecta","volume":"28","author":"Zhang","year":"2017","journal-title":"Osteoporos Int."},{"issue":"4","key":"2024012713595445700_jbmr4549-bib-0020","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ajhg.2013.02.010","article-title":"Mutations in WNT1 cause different forms of bone fragility","volume":"92","author":"Keupp","year":"2013","journal-title":"Am J Hum Genet"},{"issue":"4","key":"2024012713595445700_jbmr4549-bib-0021","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/gim.2017.115","article-title":"Monoallelic and biallelic CREB3L1 variant causes mild and severe osteogenesis imperfecta, respectively","volume":"20","author":"Keller","year":"2018","journal-title":"Genet Med"},{"key":"2024012713595445700_jbmr4549-bib-0022","doi-asserted-by":"crossref","first-page":"11920","DOI":"10.1038\/ncomms11920","article-title":"MBTPS2 mutations cause defective regulated intramembrane proteolysis in X-linked osteogenesis imperfecta","volume":"7","author":"Lindert","year":"2016","journal-title":"Nat Commun."},{"issue":"4","key":"2024012713595445700_jbmr4549-bib-0023","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ajhg.2019.08.008","article-title":"Autosomal-recessive mutations in MESD cause osteogenesis imperfecta","volume":"105","author":"Moosa","year":"2019","journal-title":"Am J Hum Genet"},{"issue":"4","key":"2024012713595445700_jbmr4549-bib-0024","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/jmedgenet-2017-104999","article-title":"FAM46A mutations are responsible for autosomal recessive osteogenesis imperfecta","volume":"55","author":"Doyard","year":"2018","journal-title":"J Med Genet."},{"issue":"9","key":"2024012713595445700_jbmr4549-bib-0025","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1359\/jbmr.2000.15.9.1650","article-title":"Type V osteogenesis imperfecta: a new form of brittle bone disease","volume":"15","author":"Glorieux","year":"2000","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024012713595445700_jbmr4549-bib-0026","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ajhg.2012.06.011","article-title":"A mutation in the 5'-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus","volume":"91","author":"Semler","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"13","key":"2024012713595445700_jbmr4549-bib-0027","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2350-13-26","article-title":"Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity","volume":"10","author":"Korvala","year":"2012","journal-title":"BMC Med Genet."},{"issue":"4","key":"2024012713595445700_jbmr4549-bib-0028","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell"},{"issue":"5","key":"2024012713595445700_jbmr4549-bib-0029","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1086\/497706","article-title":"Osteoporosis-Pseudoglioma Collaborative Group. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome","volume":"77","author":"Ai","year":"2005","journal-title":"Am J Hum Genet"},{"issue":"20","key":"2024012713595445700_jbmr4549-bib-0030","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","article-title":"High bone density due to a mutation in LDL-receptor-related protein 5","volume":"346","author":"Boyden","year":"2002","journal-title":"N Engl J Med."},{"issue":"1","key":"2024012713595445700_jbmr4549-bib-0031","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/338450","article-title":"A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait","volume":"70","author":"Little","year":"2002","journal-title":"Am J Hum Genet"},{"key":"2024012713595445700_jbmr4549-bib-0032","doi-asserted-by":"crossref","first-page":"628946","DOI":"10.3389\/fendo.2020.628946","article-title":"Massively parallel sequencing for rare genetic disorders: potential and pitfalls","volume":"11","author":"McInerney-Leo","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"5","key":"2024012713595445700_jbmr4549-bib-0033","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"2024012713595445700_jbmr4549-bib-0034","doi-asserted-by":"crossref","first-page":"101453","DOI":"10.1016\/j.scr.2019.101453","article-title":"The use of simultaneous reprogramming and gene correction to generate an osteogenesis imperfecta patient COL1A1 c. 3936 G&gt;T iPSC line and an isogenic control iPSC line","volume":"38","author":"Howden","year":"2019","journal-title":"Stem Cell Res."},{"key":"2024012713595445700_jbmr4549-bib-0035","doi-asserted-by":"crossref","first-page":"101449","DOI":"10.1016\/j.scr.2019.101449","article-title":"Generation of a heterozygous COL1A1 (c.3969_3970insT) osteogenesis imperfecta mutation human iPSC line, MCRIi001-a-1, using CRISPR\/Cas9 editing","volume":"37","author":"Hosseini Far","year":"2019","journal-title":"Stem Cell Res."},{"key":"2024012713595445700_jbmr4549-bib-0036","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.cbi.2019.05.028","article-title":"Oligonucleotide therapy: an emerging focus area for drug delivery in chronic inflammatory respiratory diseases","volume":"308","author":"Mehta","year":"2019","journal-title":"Chem Biol Interact"},{"issue":"15","key":"2024012713595445700_jbmr4549-bib-0037","doi-asserted-by":"crossref","first-page":"8320","DOI":"10.3390\/ijms22158320","article-title":"Novel Aptamer-based small-molecule drug screening assay to identify potential Sclerostin inhibitors against osteoporosis","volume":"22","author":"Lee","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"2","key":"2024012713595445700_jbmr4549-bib-0038","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1172\/JCI118434","article-title":"Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders","volume":"97","author":"Wang","year":"1996","journal-title":"J Clin Invest"},{"key":"2024012713595445700_jbmr4549-bib-0039","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1074\/jbc.RA119.011440","article-title":"Antisense oligonucleotides targeting Notch2 ameliorate the osteopenic phenotype in a mouse model of Hajdu-Cheney syndrome","volume":"295","author":"Canalis","year":"2020","journal-title":"J Biol Chem"},{"issue":"5","key":"2024012713595445700_jbmr4549-bib-0040","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2174\/1566523215666150812115730","article-title":"Therapy for dominant inherited diseases by allele-specific RNA interference: successes and pitfalls","volume":"15","author":"Trochet","year":"2015","journal-title":"Curr Gene Ther."},{"issue":"10","key":"2024012713595445700_jbmr4549-bib-0041","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.7150\/ijms.5774","article-title":"Allele dependent silencing of collagen type I using small interfering RNAs targeting 3'UTR Indels\u2014a novel therapeutic approach in osteogenesis imperfecta","volume":"10","author":"Lindahl","year":"2013","journal-title":"Int J Med Sci."},{"issue":"5","key":"2024012713595445700_jbmr4549-bib-0042","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/ejhg.2013.198","article-title":"Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta","volume":"22","author":"Rousseau","year":"2014","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"2024012713595445700_jbmr4549-bib-0043","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s13346-021-00926-5","article-title":"Tailor-made oligonucleotide-loaded lipid-polymer nanosystems designed for bone gene therapy","volume":"11","author":"Garc\u00eda-Garc\u00eda","year":"2021","journal-title":"Drug Deliv Transl Res."},{"issue":"9","key":"2024012713595445700_jbmr4549-bib-0044","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1080\/10837450.2020.1798458","article-title":"Bisphosphonate-functionalized micelles for targeted delivery of curcumin to metastatic bone cancer","volume":"25","author":"Kamble","year":"2020","journal-title":"Pharm Dev Technol."},{"key":"2024012713595445700_jbmr4549-bib-0045","doi-asserted-by":"crossref","first-page":"100105","DOI":"10.1016\/j.mtbio.2021.100105","article-title":"Designing biomaterials for the delivery of RNA therapeutics to stimulate bone healing","volume":"10","author":"Andr\u00e9e","year":"2021","journal-title":"Mater Today Bio."},{"issue":"8","key":"2024012713595445700_jbmr4549-bib-0046","first-page":"902","article-title":"Oligonucleotide therapies in the treatment of arthritis: a narrative review","volume":"9","author":"Wijesinghe","year":"2021","journal-title":"Biomedicine."},{"issue":"21","key":"2024012713595445700_jbmr4549-bib-0047","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"2024012713595445700_jbmr4549-bib-0048","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol."},{"issue":"3","key":"2024012713595445700_jbmr4549-bib-0049","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/6529","article-title":"Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta","volume":"5","author":"Horwitz","year":"1999","journal-title":"Nat Med."},{"issue":"1","key":"2024012713595445700_jbmr4549-bib-0050","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1043454211426576","article-title":"Osteogenesis imperfecta and bone marrow transplant","volume":"29","author":"Madonia","year":"2012","journal-title":"J Pediatr Oncol Nurs."},{"issue":"2","key":"2024012713595445700_jbmr4549-bib-0051","first-page":"1","article-title":"The use of stem cells to treat osteogenesis imperfecta","volume":"3","author":"Issel","year":"2019","journal-title":"Stem Cell Res Int."},{"issue":"Suppl 2","key":"2024012713595445700_jbmr4549-bib-0052","doi-asserted-by":"crossref","first-page":"ii29","DOI":"10.1136\/ard.61.suppl_2.ii29","article-title":"Mesenchymal stem cells. A potential source for skeletal repair","volume":"61","author":"Fibbe","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2024012713595445700_jbmr4549-bib-0053","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4236\/ojgen.2013.31006","article-title":"Cell therapy of a patient with type III osteogenesis imperfecta caused by mutation in COL1A2 gene and unstable collagen type I","volume":"3","author":"Majka","year":"2013","journal-title":"Open J Genet."},{"issue":"11","key":"2024012713595445700_jbmr4549-bib-0054","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/01.TP.0000159029.48678.93","article-title":"Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta","volume":"79","author":"Le Blanc","year":"2005","journal-title":"Transplantation."},{"issue":"1","key":"2024012713595445700_jbmr4549-bib-0055","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1002\/ctm2.265","article-title":"Reiterative infusions of MSCs improve pediatric osteogenesis imperfecta eliciting a pro-osteogenic paracrine response: TERCELOI clinical trial","volume":"11","author":"Infante","year":"2021","journal-title":"Clin Transl Med."},{"issue":"4","key":"2024012713595445700_jbmr4549-bib-0056","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11914-020-00594-3","article-title":"Stem cell therapy as a treatment for osteogenesis imperfecta","volume":"18","author":"G\u00f6therstr\u00f6m","year":"2020","journal-title":"Curr Osteoporos Rep."},{"issue":"4","key":"2024012713595445700_jbmr4549-bib-0057","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/GRF.0000000000000656","article-title":"Mesenchymal stem cell therapy for osteogenesis imperfecta","volume":"64","author":"G\u00f6therstr\u00f6m","year":"2021","journal-title":"Clin Obstet Gynecol."},{"issue":"9","key":"2024012713595445700_jbmr4549-bib-0058","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1182\/blood-2011-12-400085","article-title":"Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms","volume":"120","author":"Otsuru","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2024012713595445700_jbmr4549-bib-0059","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00223-018-0504-3","article-title":"Bone marrow transplantation for treatment of the Col1a2+\/G610C osteogenesis imperfecta mouse model","volume":"104","author":"Lee","year":"2019","journal-title":"Calcif Tissue Int."},{"issue":"4","key":"2024012713595445700_jbmr4549-bib-0060","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/stem.3133","article-title":"Engraftment of skeletal progenitor cells by bone-directed transplantation improves osteogenesis imperfecta murine bone phenotype","volume":"38","author":"Sinder","year":"2020","journal-title":"Stem Cells"},{"issue":"10","key":"2024012713595445700_jbmr4549-bib-0061","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3390\/biom11101493","article-title":"Osteogenesis imperfecta: current and prospective therapies","volume":"11","author":"Botor","year":"2021","journal-title":"Biomolecules."},{"issue":"10","key":"2024012713595445700_jbmr4549-bib-0062","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3727\/096368914X685410","article-title":"Ex vivo expanded allogeneic mesenchymal stem cells with bone marrow transplantation improved osteogenesis in infants with severe hypophosphatasia","volume":"24","author":"Taketani","year":"2015","journal-title":"Cell Transplant."},{"issue":"14","key":"2024012713595445700_jbmr4549-bib-0063","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.3390\/jcm10143141","article-title":"Restoration of osteogenesis by CRISPR\/Cas9 genome editing of the mutated COL1A1 gene in osteogenesis imperfecta","volume":"10","author":"Jung","year":"2021","journal-title":"J Clin Med."},{"key":"2024012713595445700_jbmr4549-bib-0064","doi-asserted-by":"crossref","first-page":"111917","DOI":"10.1016\/j.biopha.2021.111917","article-title":"CRISPR: history and perspectives to the future","volume":"141","author":"Kozovska","year":"2021","journal-title":"Biomed Pharmacother."},{"issue":"4","key":"2024012713595445700_jbmr4549-bib-0065","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/sj.gt.3302199","article-title":"Gene therapy approaches for osteogenesis imperfecta","volume":"11","author":"Niyibizi","year":"2004","journal-title":"Gene Ther."},{"issue":"5","key":"2024012713595445700_jbmr4549-bib-0066","doi-asserted-by":"crossref","first-page":"e3015","DOI":"10.1002\/jgm.3015","article-title":"Gene therapy clinical trials worldwide to 2017: an update","volume":"20","author":"Ginn","year":"2018","journal-title":"J Gene Med"},{"issue":"6648","key":"2024012713595445700_jbmr4549-bib-0067","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/38410","article-title":"Gene therapy\u2014promises, problems and prospects","volume":"389","author":"Verma","year":"1997","journal-title":"Nature."},{"issue":"9","key":"2024012713595445700_jbmr4549-bib-0068","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nbt0997-871","article-title":"Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo","volume":"15","author":"Zufferey","year":"1997","journal-title":"Nat Biotechnol."},{"issue":"12","key":"2024012713595445700_jbmr4549-bib-0069","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/JOM.0000000000000879","article-title":"Risks associated with lentiviral vector exposures and prevention strategies","volume":"58","author":"Schlimgen","year":"2016","journal-title":"J Occup Environ Med."},{"issue":"20","key":"2024012713595445700_jbmr4549-bib-0070","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1182\/blood-2010-09-306761","article-title":"Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection","volume":"117","author":"Biffi","year":"2011","journal-title":"Blood."},{"issue":"1","key":"2024012713595445700_jbmr4549-bib-0071","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jbmr.201","article-title":"Prolonged survival and phenotypic correction of Akp2(\u2212\/\u2212) hypophosphatasia mice by lentiviral gene therapy","volume":"26","author":"Yamamoto","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2024012713595445700_jbmr4549-bib-0072","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0959-437X(93)90126-A","article-title":"Gene therapy: adenovirus vectors","volume":"3","author":"Kozarsky","year":"1993","journal-title":"Curr Opin Genet Dev."},{"issue":"5448","key":"2024012713595445700_jbmr4549-bib-0073","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1126\/science.286.5448.2244","article-title":"Gene therapy death prompts review of adenovirus vector","volume":"286","author":"Marshall","year":"1999","journal-title":"Science."},{"issue":"2","key":"2024012713595445700_jbmr4549-bib-0074","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02678146","article-title":"In vitro and in vivo induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene","volume":"68","author":"Cheng","year":"2001","journal-title":"Calcif Tissue Int."},{"issue":"24","key":"2024012713595445700_jbmr4549-bib-0075","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1038\/sj.gt.3302106","article-title":"Ex vivo gene therapy in autologous bone marrow stromal stem cells for tissue-engineered maxillofacial bone regeneration","volume":"10","author":"Chang","year":"2003","journal-title":"Gene Ther."},{"issue":"8","key":"2024012713595445700_jbmr4549-bib-0076","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1089\/10430340050015248","article-title":"Gene therapy-directed osteogenesis: BMP-7-transduced human fibroblasts form bone in vivo","volume":"11","author":"Krebsbach","year":"2000","journal-title":"Hum Gene Ther."},{"issue":"6","key":"2024012713595445700_jbmr4549-bib-0077","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S8756-3282(99)00086-1","article-title":"Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone","volume":"24","author":"Musgrave","year":"1999","journal-title":"Bone."},{"issue":"17","key":"2024012713595445700_jbmr4549-bib-0078","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/sj.gt.3302298","article-title":"Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery","volume":"11","author":"Kang","year":"2004","journal-title":"Gene Ther."},{"issue":"6","key":"2024012713595445700_jbmr4549-bib-0079","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1128\/JVI.75.6.2729-2740.2001","article-title":"Evolutionary relationships among parvoviruses: virus-host coevolution among autonomous primate parvoviruses and links between adeno-associated and avian parvoviruses","volume":"75","author":"Lukashov","year":"2001","journal-title":"J Virol."},{"issue":"3685","key":"2024012713595445700_jbmr4549-bib-0080","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-associated defective virus particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science."},{"issue":"1","key":"2024012713595445700_jbmr4549-bib-0081","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0042-6822(67)90251-6","article-title":"Studies on the relationship between adeno-associated virus type I (AAV-1) and adenoviruses. I. Replication of AAV-1 in certain cell cultures and its effect on helper adenovirus","volume":"32","author":"Casto","year":"1967","journal-title":"Virology."},{"issue":"6","key":"2024012713595445700_jbmr4549-bib-0082","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1128\/JVI.74.6.2777-2785.2000","article-title":"Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors","volume":"74","author":"Bartlett","year":"2000","journal-title":"J Virol."},{"issue":"2","key":"2024012713595445700_jbmr4549-bib-0083","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nbt1182","article-title":"Directed evolution of adeno-associated virus yields enhanced gene delivery vectors","volume":"24","author":"Maheshri","year":"2006","journal-title":"Nat Biotechnol."},{"key":"2024012713595445700_jbmr4549-bib-0084","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fmicb.2011.00204","article-title":"Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity","volume":"2","author":"Bartel","year":"2011","journal-title":"Front Microbiol."},{"key":"2024012713595445700_jbmr4549-bib-0085","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cobme.2018.09.004","article-title":"Adeno-associated virus (AAV) vectors: rational design strategies for capsid engineering","volume":"7","author":"Lee","year":"2018","journal-title":"Curr Opin Biomed Eng"},{"key":"2024012713595445700_jbmr4549-bib-0086","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.omtm.2019.08.010","article-title":"Targeting adeno-associated virus vectors for local delivery to fractures and systemic delivery to the skeleton","volume":"15","author":"Lee","year":"2019","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"9","key":"2024012713595445700_jbmr4549-bib-0087","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/gt.2015.40","article-title":"Local administration of AAV-DJ pseudoserotype expressing COX2 provided early onset of transgene expression and promoted bone fracture healing in mice","volume":"22","author":"Lakhan","year":"2015","journal-title":"Gene Ther."},{"key":"2024012713595445700_jbmr4549-bib-0088","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.omtm.2020.04.010","article-title":"Bone-targeting AAV-mediated gene silencing in osteoclasts for osteoporosis therapy","volume":"17","author":"Yang","year":"2020","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"1","key":"2024012713595445700_jbmr4549-bib-0089","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1038\/s41467-019-10809-6","article-title":"Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis","volume":"10","author":"Yang","year":"2019","journal-title":"Nat Commun."},{"issue":"7","key":"2024012713595445700_jbmr4549-bib-0090","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/mt.2008.99","article-title":"Bone-protective effects of nonviral gene therapy with folate-chitosan DNA nanoparticle containing interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis","volume":"16","author":"Fernandes","year":"2008","journal-title":"Mol Ther."},{"issue":"3","key":"2024012713595445700_jbmr4549-bib-0091","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/jbm.a.32441","article-title":"Calcium phosphate-DNA nanoparticle gene delivery from alginate hydrogels induces in vivo osteogenesis","volume":"92","author":"Krebs","year":"2010","journal-title":"J Biomed Mater Res A"},{"key":"2024012713595445700_jbmr4549-bib-0092","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.msec.2018.06.047","article-title":"Prolonged release of bone morphogenetic protein-2 in vivo by gene transfection with DNA-functionalized calcium phosphate nanoparticle-loaded collagen scaffolds","volume":"92","author":"Tenkumo","year":"2018","journal-title":"Mater Sci Eng C Mater Biol Appl."},{"issue":"5","key":"2024012713595445700_jbmr4549-bib-0093","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biomaterials.2009.10.011","article-title":"Polyethylenimine-PEG coated albumin nanoparticles for BMP-2 delivery","volume":"31","author":"Zhang","year":"2010","journal-title":"Biomaterials."},{"key":"2024012713595445700_jbmr4549-bib-0094","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.2147\/IJN.S139775","article-title":"A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy","volume":"12","author":"Cai","year":"2017","journal-title":"Int J Nanomed."},{"issue":"9","key":"2024012713595445700_jbmr4549-bib-0095","first-page":"2905","article-title":"Exosome-guided bone targeted delivery of Antagomir-188 as an anabolic therapy for bone loss","volume":"6","author":"Hu","year":"2021","journal-title":"Bioact Mater."},{"issue":"5","key":"2024012713595445700_jbmr4549-bib-0096","first-page":"437","article-title":"Onasemnogene Abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"26","author":"Naveed","year":"2021","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"2024012713595445700_jbmr4549-bib-0097","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/humu.22915","article-title":"Mutation update for COL2A1 gene variants associated with type II collagenopathies","volume":"37","author":"Barat-Houari","year":"2016","journal-title":"Hum Mutat."},{"issue":"5","key":"2024012713595445700_jbmr4549-bib-0098","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2018-07-820720","article-title":"Update on clinical gene therapy for hemophilia","volume":"133","author":"Perrin","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2024012713595445700_jbmr4549-bib-0099","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/sj.gt.3300600","article-title":"Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (MDX) mice","volume":"5","author":"Yang","year":"1998","journal-title":"Gene Ther."},{"issue":"1","key":"2024012713595445700_jbmr4549-bib-0100","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/jcb.1209","article-title":"Transfer of proalpha2(I) cDNA into cells of a murine model of human Osteogenesis Imperfecta restores synthesis of type I collagen comprised of alpha1(I) and alpha2(I) heterotrimers in vitro and in vivo","volume":"83","author":"Niyibizi","year":"2001","journal-title":"J Cell Biochem"},{"issue":"6213","key":"2024012713595445700_jbmr4549-bib-0101","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"issue":"4","key":"2024012713595445700_jbmr4549-bib-0102","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nmeth.2857","article-title":"Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects","volume":"11","author":"Shen","year":"2014","journal-title":"Nat Methods."},{"issue":"1","key":"2024012713595445700_jbmr4549-bib-0103","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1038\/s41467-020-18715-y","article-title":"Engineering domain-inlaid SaCas9 adenine base editors with reduced RNA off-targets and increased on-target DNA editing","volume":"11","author":"Nguyen Tran","year":"2020","journal-title":"Nat Commun."},{"issue":"13","key":"2024012713595445700_jbmr4549-bib-0104","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1093\/nar\/gkv601","article-title":"Development of an intein-mediated split-Cas9 system for gene therapy","volume":"43","author":"Truong","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"2024012713595445700_jbmr4549-bib-0105","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med."},{"issue":"7603","key":"2024012713595445700_jbmr4549-bib-0106","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"issue":"7785","key":"2024012713595445700_jbmr4549-bib-0107","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"issue":"2","key":"2024012713595445700_jbmr4549-bib-0108","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s10038-017-0352-4","article-title":"In vivo genome editing via the HITI method as a tool for gene therapy","volume":"63","author":"Suzuki","year":"2018","journal-title":"J Hum Genet."},{"issue":"24","key":"2024012713595445700_jbmr4549-bib-0109","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1093\/bioinformatics\/btv537","article-title":"Cas-designer: a web-based tool for choice of CRISPR-Cas9 target sites","volume":"31","author":"Park","year":"2015","journal-title":"Bioinformatics."},{"issue":"1","key":"2024012713595445700_jbmr4549-bib-0110","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12015-009-9056-2","article-title":"Genomic profiling of mesenchymal stem cells","volume":"5","author":"Menicanin","year":"2009","journal-title":"Stem Cell Rev Rep."},{"issue":"7866","key":"2024012713595445700_jbmr4549-bib-0111","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","article-title":"Base editing of haematopoietic stem cells rescues sickle cell disease in mice","volume":"595","author":"Newby","year":"2021","journal-title":"Nature"},{"issue":"5","key":"2024012713595445700_jbmr4549-bib-0112","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41556-021-00671-4","article-title":"Eliminating base-editor-induced genome-wide and transcriptome-wide off-target mutations","volume":"23","author":"Wang","year":"2021","journal-title":"Nat Cell Biol."},{"issue":"5","key":"2024012713595445700_jbmr4549-bib-0113","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1073\/pnas.90.5.1701","article-title":"Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta","volume":"90","author":"Chipman","year":"1993","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"2024012713595445700_jbmr4549-bib-0114","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1371\/journal.pgen.0040007","article-title":"ER stress-mediated apoptosis in a new mouse model of osteogenesis imperfecta","volume":"4","author":"Lisse","year":"2008","journal-title":"PLoS Genet"},{"issue":"2","key":"2024012713595445700_jbmr4549-bib-0115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1359\/jbmr.090720","article-title":"Variable bone fragility associated with an Amish COL1A2 variant and a knock-in mouse model","volume":"25","author":"Daley","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"5924","key":"2024012713595445700_jbmr4549-bib-0116","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/304315a0","article-title":"Embryonic lethal mutation in mice induced by retrovirus insertion into the alpha 1(I) collagen gene","volume":"304","author":"Schnieke","year":"1983","journal-title":"Nature"},{"issue":"18","key":"2024012713595445700_jbmr4549-bib-0117","doi-asserted-by":"crossref","first-page":"7145","DOI":"10.1073\/pnas.87.18.7145","article-title":"Transgenic mouse model of the mild dominant form of osteogenesis imperfecta","volume":"87","author":"Bonadio","year":"1990","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2024012713595445700_jbmr4549-bib-0118","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/332131a0","article-title":"Perinatal lethal osteogenesis imperfecta in transgenic mice bearing an engineered mutant pro-\u03b11(I) collagen gene","volume":"332","author":"Stacey","year":"1988","journal-title":"Nature."},{"key":"2024012713595445700_jbmr4549-bib-0119","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.bone.2019.07.021","article-title":"A novel transgenic murine model with persistently brittle bones simulating osteogenesis imperfecta type I","volume":"127","author":"Liu","year":"2019","journal-title":"Bone."},{"issue":"1","key":"2024012713595445700_jbmr4549-bib-0120","doi-asserted-by":"crossref","first-page":"11717","DOI":"10.1038\/s41598-017-10343-9","article-title":"An ENU-induced splice site mutation of mouse Col1a1 causing recessive osteogenesis imperfecta and revealing a novel splicing rescue","volume":"7","author":"Tabeta","year":"2017","journal-title":"Sci Rep."},{"issue":"53","key":"2024012713595445700_jbmr4549-bib-0121","doi-asserted-by":"crossref","first-page":"37923","DOI":"10.1074\/jbc.274.53.37923","article-title":"Use of the Cre\/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha1(I) G349C substitution. Variability in phenotype in BrtlIV mice","volume":"274","author":"Forlino","year":"1999","journal-title":"J Biol Chem."},{"issue":"6","key":"2024012713595445700_jbmr4549-bib-0122","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/jbmr.2177","article-title":"First mouse model for combined osteogenesis imperfecta and Ehlers-Danlos syndrome","volume":"29","author":"Chen","year":"2014","journal-title":"J Bone Miner Res."},{"issue":"34","key":"2024012713595445700_jbmr4549-bib-0123","doi-asserted-by":"crossref","first-page":"23373","DOI":"10.1016\/S0021-9258(18)54506-3","article-title":"Transgenic mice that express a mini-gene version of the human gene for type I procollagen (COL1A1) develop a phenotype resembling a lethal form of osteogenesis imperfecta","volume":"266","author":"Khillan","year":"1991","journal-title":"J Biol Chem."},{"issue":"3","key":"2024012713595445700_jbmr4549-bib-0124","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/jbmr.2363","article-title":"A transgenic mouse model of OI type V supports a neomorphic mechanism of the IFITM5 mutation","volume":"30","author":"Lietman","year":"2015","journal-title":"J Bone Miner Res."},{"issue":"13","key":"2024012713595445700_jbmr4549-bib-0125","doi-asserted-by":"crossref","first-page":"100650","DOI":"10.1016\/j.bonr.2020.100650","article-title":"New Ifitm5 S42L mouse model for atypical type VI OI connects types V and VI Osteogenesis Imperfecta","volume":"20","author":"Guterman-Ram","year":"2020","journal-title":"Bone Rep."},{"issue":"7","key":"2024012713595445700_jbmr4549-bib-0126","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.1892","article-title":"A mouse model for human osteogenesis imperfecta type VI","volume":"28","author":"Bogan","year":"2013","journal-title":"J Bone Miner Res."},{"issue":"22","key":"2024012713595445700_jbmr4549-bib-0127","doi-asserted-by":"crossref","first-page":"17253","DOI":"10.1074\/jbc.M110.102228","article-title":"Prolyl 3-hydroxylase 1 null mice display abnormalities in fibrillar collagen-rich tissues such as tendons, skin, and bones","volume":"285","author":"Vranka","year":"2010","journal-title":"J Biol Chem"},{"issue":"12","key":"2024012713595445700_jbmr4549-bib-0128","doi-asserted-by":"crossref","first-page":"e1000750","DOI":"10.1371\/journal.pgen.1000750","article-title":"Severe osteogenesis imperfecta in cyclophilin B-deficient mice","volume":"5","author":"Choi","year":"2009","journal-title":"PLoS Genet"},{"issue":"6","key":"2024012713595445700_jbmr4549-bib-0129","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1083\/jcb.150.6.1499","article-title":"Embryonic lethality of molecular chaperone hsp47 knockout mice is associated with defects in collagen biosynthesis","volume":"150","author":"Nagai","year":"2000","journal-title":"J Cell Biol."},{"issue":"18","key":"2024012713595445700_jbmr4549-bib-0130","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1093\/hmg\/ddu197","article-title":"Connective tissue alterations in Fkbp10\u2212\/\u2212 mice","volume":"23","author":"Lietman","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"6","key":"2024012713595445700_jbmr4549-bib-0131","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1359\/jbmr.081248","article-title":"Positive regulation of adult bone formation by osteoblast-specific transcription factor osterix","volume":"24","author":"Baek","year":"2009","journal-title":"J Bone Miner Res."},{"issue":"15","key":"2024012713595445700_jbmr4549-bib-0132","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1093\/hmg\/ddu117","article-title":"The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutations","volume":"23","author":"Joeng","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2024012713595445700_jbmr4549-bib-0133","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41413-021-00170-0","article-title":"The WNT1G177C mutation specifically affects skeletal integrity in a mouse model of osteogenesis imperfecta type XV","volume":"9","author":"Vollersen","year":"2021","journal-title":"Bone Res."},{"issue":"428","key":"2024012713595445700_jbmr4549-bib-0134","doi-asserted-by":"crossref","first-page":"ra49","DOI":"10.1126\/scisignal.aad9055","article-title":"Mice lacking the intracellular cation channel TRIC-B have compromised collagen production and impaired bone mineralization","volume":"9","author":"Zhao","year":"2016","journal-title":"Sci Signal."},{"issue":"9","key":"2024012713595445700_jbmr4549-bib-0135","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol Ther"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4549","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4549","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/37\/5\/826\/55460267\/jbmr4549.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/37\/5\/826\/55460267\/jbmr4549.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:08:47Z","timestamp":1710328127000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/37\/5\/826-836\/7499945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":135,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3,20]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4549","relation":{"has-review":[{"id-type":"doi","id":"10.1002\/JBMR.4549\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4549\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4549\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4549\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4549\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4549\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4549\/v2\/review2","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2021-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}